keyword
MENU ▼
Read by QxMD icon Read
search

Brimonidine

keyword
https://www.readbyqxmd.com/read/29135708/high-permeability-and-intercellular-space-widening-with-brimonidine-tartrate-eye-drops-in-cultured-stratified-human-corneal-epithelial-sheets
#1
Yumi Hashimoto, Seiichi Yokoo, Tomohiko Usui, Yukiko Tsubota, Satoru Yamagami
PURPOSE: To investigate the toxicity of topical glaucoma medications using cultured stratified human corneal epithelial sheets (HCES). METHODS: HCES were exposed for 30 minutes to the following glaucoma medications: 0.1% brimonidine with sodium chlorite as the preservative, 0.005% latanoprost with 0.02% benzalkonium chloride (BAC) as the preservative, and 0.5% timolol with 0.005% BAC as the preservative. Then, cell viability and barrier function were tested by the WST-1 assay and carboxyfluorescein permeability assay, respectively...
November 13, 2017: Cornea
https://www.readbyqxmd.com/read/29120262/evaluation-of-efficacy-and-safety-of-brimonidine-tartrate-ophthalmic-solution-0-025-for-treatment-of-ocular-redness
#2
Gail L Torkildsen, Christine M Sanfilippo, Heleen H DeCory, Paul J Gomes
Purpose/Aims: This study assessed the efficacy and safety of brimonidine tartrate ophthalmic solution, 0.025% for treating ocular redness in adult subjects. MATERIALS AND METHODS: This was a single-center, double-masked, randomized, vehicle-controlled, parallel-group study in subjects ≥40 years, with ocular redness. Subjects were randomized 2:1 to brimonidine or vehicle, instilled QID for four weeks. Subjects completed four visits, the last occurring one week after treatment discontinuation...
November 9, 2017: Current Eye Research
https://www.readbyqxmd.com/read/29104721/topical-a-agonist-therapy-for-persistent-facial-erythema-of-rosacea-and-the-addition-of-oxmetazoline-to-the-treatment-armamentarium-where-are-we-now
#3
REVIEW
James Q Del Rosso
The presence of vasoactivity in rosacea-affected skin led to the development of two topical α-adrenergic receptor agonists, brimonidine tartrate 0.5% gel and oxymetazoline hydrochloride 1% cream, both approved by the United States Food and Drug Administration for treatment of persistent facial erythema of rosacea. In this article, the author discusses challenges related to the treatment of persistent facial erythema of rosacea and the use of a-agonist therapy. The author also discusses cases of worsening of facial erythema after the application of brimonidine, as well as briefly reviews recently reported clinical data on oxymetazoline...
July 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/29094614/role-of-topical-oxymetazoline-for-management-of-erythematotelangiectatic-rosacea
#4
Rebecca M Hoover, John Erramouspe
OBJECTIVE: To review and summarize topical oxymetazoline's pharmacology, pharmacokinetics, efficacy, safety, cost, and place in therapy for persistent redness associated with erythematotelangiectatic rosacea. DATA SOURCES: Literature searches of MEDLINE (1975 to September 2017), International Pharmaceutical Abstracts (1975 to September 2017), and Cochrane Database (publications through September 2017) using the terms rosacea, persistent redness, α -agonist, and oxymetazoline...
November 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29077635/topical-brimonidine-tartrate-0-33-gel-on-postlaser-erythema-our-experience-and-review-of-the-literature
#5
Sang Ju Lee, Hyeree Kim, Hei Sung Kim
No abstract text is available yet for this article.
October 26, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/29057117/a-masked-randomized-phase-3-comparison-of-triple-fixed-combination-bimatoprost-brimonidine-timolol-versus-fixed-combination-brimonidine-timolol-for-lowering-intraocular-pressure
#6
Curt Hartleben, Juan Camilo Parra, Amy Batoosingh, Paula Bernstein, Margot Goodkin
OBJECTIVE: To evaluate the efficacy and safety of triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC) versus dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC) in primary open-angle glaucoma and ocular hypertension. METHODS: Patients with intraocular pressure (IOP) ≥23 and ≤34 mmHg were randomized to twice-daily TFC or DFC. The primary variable is the change in worse eye mean IOP from baseline at week 12 (modified intent-to-treat (mITT) population)...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/29031658/randomized-controlled-pilot-study-of-the-preoperative-use-of-brimonidine-0-33-topical-gel-for-hemostasis-in-mohs-micrographic-surgery
#7
Edward Chen, Raj Ajay Patel, Young Jin Kwak, Conway C Huang
BACKGROUND: Brimonidine topical gel may be useful in cutaneous surgical procedures because of its vasoconstricting properties. OBJECTIVE: Assess the hemostatic effect of topically applied brimonidine in patients being treated with anticoagulants and undergoing Mohs micrographic surgery (MMS). METHODS: Subjects undergoing MMS were randomly assigned to the control (n = 10) or study arm (n = 14). Controls received standard-of-care MMS, whereas the study arm received the same and preoperative application of brimonidine...
December 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29026287/ocular-pharmacokinetics-and-tolerability-of-bimatoprost-ophthalmic-solutions-administered-once-or-twice-daily-in-rabbits-and-clinical-dosing-implications
#8
Jie Shen, Margot L Goodkin, Warren Tong, Mayssa Attar
PURPOSE: Fixed-combination medications can benefit patients requiring multiple agents to lower their intraocular pressure (IOP), but combining agents with complementary mechanisms of action is challenging if their dosing frequency differs. This study compares in vivo pharmacokinetic and ocular tolerability of bimatoprost 0.01% ophthalmic solutions dosed once or twice daily. Reports of twice-daily dosing in glaucoma patients are also reviewed. METHODS: New Zealand White rabbits were administered bimatoprost 0...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28938378/severe-corneal-disorders-developed-after-brimonidine-tartrate-ophthalmic-solution-use
#9
Yuko Maruyama, Yoko Ikeda, Norihiko Yokoi, Kazuhiko Mori, Hiroaki Kato, Morio Ueno, Shigeru Kinoshita, Chie Sotozono
PURPOSE: The primary side effects associated with 0.1% brimonidine tartrate (BT) ophthalmic solution with sodium chlorite are allergic conjunctivitis, blepharitis, and conjunctival hyperemia. However, cornea-related side effects are rare. In this study, we report 2 similar cases in which corneal neovascularization, corneal infiltration, and corneal opacity developed after BT eye-drop use. METHODS: Retrospective report of 2 cases of corneal infiltration after BT eye-drop use...
December 2017: Cornea
https://www.readbyqxmd.com/read/28915286/treatment-of-rosacea-with-concomitant-use-of-topical-ivermectin-1-cream-and-brimonidine-0-33-gel-a-randomized-vehicle-controlled-study
#10
Linda Stein Gold, Kim Papp, Charles Lynde, Edward Lain, Melinda Gooderham, Sandra Johnson, Nabil Kerrouche
BACKGROUND: There is currently a lack of data on the simultaneous treatment of different features of rosacea. Individually, ivermectin 1% (IVM) cream and brimonidine 0.33% (BR) gel have demonstrated efficacy on inflammatory lesions and persistent erythema, respectively. OBJECTIVE: To evaluate the efficacy, safety, patient satisfaction, and optimal timing of administration of IVM associated with BR (IVM+BR) versus their vehicles in rosacea (investigator global assessment [IGA] ≥3)...
September 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28900607/de-novo-intraocular-amyloid-deposition-after-hepatic-transplantation-in-familial-amyloidotic-polyneuropathy
#11
Ivo Filipe Gama, Leonor Duarte Almeida
The familiar amyloid polyneuropathy (FAP) is a rare autosomal-dominant systemic amyloidosis. Amyloid deposition occurs more frequently and extensively in the vitq. The increase in intraocular pressure (IOP) is a result of deposition of transthyretin (TTR) in trabecular meshwork. Rarely, the amyloid deposition in anterior segment can be more exuberant than in posterior segment. A 42 years old man, with FAP (Val30Met mutation), liver transplantation in 1997. He was asymptomatic, without any significant ocular abnormality until 2011...
August 24, 2017: World Journal of Transplantation
https://www.readbyqxmd.com/read/28889348/treatment-of-erythemato-telangiectatic-rosacea-with-brimonidine-alone-or-combined-with-vascular-laser-based-on-preliminary-instrumental-evaluation-of-the-vascular-component
#12
Giuseppe Micali, Federica Dall'Oglio, Anna Elisa Verzì, Ivano Luppino, Karishma Bhatt, Francesco Lacarrubba
The purpose of this study is to evaluate the outcome of a series of patients with erythematotelangiectatic rosacea (ETR) affected by persistent erythema and varying degree of telangiectasias being treated with brimonidine alone or combined with a vascular laser based on the type of vascular components preliminarily evaluated by clinical and instrumental observation. Ten patients affected by ETR were enrolled in a pilot, open study. Instrumental evaluation included erythema-directed digital photography by VISIA-CR™ system and X10 dermoscopy...
September 9, 2017: Lasers in Medical Science
https://www.readbyqxmd.com/read/28889125/brimonidine-protects-auditory-hair-cells-from-in-vitro-induced-toxicity-of-gentamicin
#13
Maurizio Cortada, Soledad Levano, Daniel Bodmer
Brimonidine, an alpha-2 adrenergic receptor (α2-AR) agonist, has neuroprotective effects in the visual system and in spiral ganglion neurons. Auditory hair cells (HCs) express all 3 α2-AR subtypes, but their roles in HCs remain unknown. This study investigated the effects of brimonidine on auditory HCs that were also exposed to gentamicin, which is toxic to HCs. Organ of Corti explants were exposed to gentamicin in the presence or absence of brimonidine, and the α2-AR protein expression levels and Erk1/2 and Akt phosphorylation levels were determined...
2017: Audiology & Neuro-otology
https://www.readbyqxmd.com/read/28874390/brimonidine-gel-and-adverse-cardiovascular-effects
#14
(no author information available yet)
No abstract text is available yet for this article.
September 5, 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28865952/sedative-and-physiological-effects-of-brimonidine-tartrate-ophthalmic-solution-in-healthy-cats
#15
Niwako Ogata, Teppei Kanda, Mizuki Kawahata, Takayasu Ichikawa, Yuki Matsumoto, Waka Morimitsu, Yukiko Nishino, Takamasa Itoi, Kayo Furumoto
OBJECTIVE: To determine the effects of brimonidine tartrate ophthalmic solution on sedation, heart rate (HR), respiratory frequency (fR), rectal temperature (RT) and noninvasive mean arterial pressure (MAP) in healthy cats. STUDY DESIGN: Randomized, blinded crossover study, with 1 week washout between treatments. ANIMALS: Six healthy purpose-bred cats. METHODS: Brimonidine tartrate ophthalmic solution 0.1% (one or two drops; 58...
July 3, 2017: Veterinary Anaesthesia and Analgesia
https://www.readbyqxmd.com/read/28859698/validated-hplc-dad-method-for-the-simultaneous-determination-of-six-selected-drugs-used-in-the-treatment-of-glaucoma
#16
Mostafa M Baker, Tarek S Belal
This work presents a simple, sensitive, and generic HPLC–diode-array detection method for the simultaneous determination of six drugs prescribed for the treatment of open-angle glaucoma and ocular hypertension. The investigated drugs include brimonidine tartarate (BMN), acetazolamide (AZA), brinzomaide (BZA), dorzolamide HCl (DZA), levobunolol HCl (LVB), and timolol maleate (TIM). Efficient chromatographic separation was achieved using a Thermo Hypersil BDS C18 column (4.6 × 250 mm, 5 µm) with a mobile phase consisting of phosphate buffer pH 5 and acetonitrile in a ratio of 78 + 22...
September 1, 2017: Journal of AOAC International
https://www.readbyqxmd.com/read/28856599/erratum-to-multicenter-randomized-investigator-masked-study-comparing-brimonidine-tartrate-0-1-and-timolol-maleate-0-5-as-adjunctive-therapies-to-prostaglandin-analogues-in-normal-tension-glaucoma
#17
Shiro Mizoue, Koji Nitta, Motohiro Shirakashi, Akiyoshi Nitta, Shigeki Yamabayashi, Tairo Kimura, Toshihiko Ueda, Ryuji Takeda, Shun Matsumoto, Keiji Yoshikawa
No abstract text is available yet for this article.
September 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28837365/oxymetazoline-hydrochloride-cream-for-facial-erythema-associated-with-rosacea
#18
REVIEW
Nupur U Patel, Shweta Shukla, Jessica Zaki, Steven R Feldman
Rosacea is a chronic skin condition characterized by transient and persistent erythema of the central face. The symptom of persistent erythema can be particularly frustrating for both patients and physicians as it is difficult to treat. Areas covered: Current treatment options for the treatment of rosacea include metronidazole, azelaic acid, sodium sulfacetamide-sulfur, and brimonidine. Until recently, brimonidine gel was the only option approved specifically for the treatment of facial erythema. However, oxymetazoline hydrochloride 1% cream is a newly FDA approved topical medication for adult rosacea patients...
October 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28825921/pure-glaucoma-drugs-are-toxic-to-immortalized-human-corneal-epithelial-cells-but-they-do-not-destabilize-lipid-membranes
#19
Alexandra Robciuc, Joanna Witos, Suvi-Katriina Ruokonen, Antti H Rantamäki, Pierre-Jean Pisella, Susanne K Wiedmer, Juha M Holopainen
PURPOSE: Most pure glaucoma drugs (pGDs) are hydrophobic substances intended to reduce elevated intraocular pressure. The aims of our study were to determine the toxicity of pGDs (brimonidine tartrate, brinzolamide, latanoprost, timolol maleate, and pilocarpine hydrochloride) on ocular surface cells and to establish whether their toxicity is subsequent to cellular membrane destabilization. METHODS: The toxicity of clinically efficient doses of pGDs was measured at different time points in a cell culture of human corneal epithelial cells using a redox indicator...
October 2017: Cornea
https://www.readbyqxmd.com/read/28819134/long-term-glaucoma-drug-delivery-using-a-topically-retained-gel-microsphere-eye-drop
#20
Morgan V Fedorchak, Ian P Conner, Joel S Schuman, Anthony Cugini, Steven R Little
The purpose of this study was to characterize and determine the efficacy of a long-term, non-invasive gel/microsphere (GMS) eye drop for glaucoma. This novel drug delivery system is comprised of a thermoresponsive hydrogel carrier and drug-loaded polymer microspheres. In vitro release of brimonidine from the GMS drops and gel properties were quantified. A single brimonidine-loaded GMS drop was administered to 5 normotensive rabbits and intraocular pressure (IOP) was monitored for 28 days. Here we report that IOP reduction in rabbits receiving a single brimonidine GMS drop was comparable to that of rabbits receiving twice daily, standard brimonidine drops...
August 17, 2017: Scientific Reports
keyword
keyword
41157
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"